pharma · Juvenile idiopathic arthritis · juvenile idiopathic arthritis
Alfasigma S.p.A.
Alfasigma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alfasigma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L04) compound in Alfasigma's portfolio. Molecular target: Tyrosine-protein kinase JAK1.
Development asset linked to Alfasigma in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.